The global cancer registry software market size was valued at USD 89.6 million in 2024 and is projected to grow from USD 103.4 million in 2025 to reach USD 213.8 million by 2033, exhibiting a CAGR of 9.5% during the forecast period (2025-2033).
Cancer registry software is a specialized digital solution designed to collect, manage, and analyze cancer-related data, supporting research, treatment planning, and public health initiatives. It enables healthcare providers, researchers, and government agencies to track oncologic disease incidence, treatment outcomes, and survival rates. By integrating patient records, pathology reports, and genetic data, the software facilitates early detection, epidemiological studies, and personalized treatment strategies.
The market is experiencing significant growth, driven by the rising global incidence of oncologic disease, the increasing need for efficient data management in oncology, and advancements in healthcare IT solutions. Government initiatives to strengthen cancer surveillance, the seamless integration of EHRs, and growing investments in research and development are further propelling market expansion. Moreover, the adoption of cloud-based technologies and AI-driven analytics is revolutionizing cancer data management and enhancing patient outcome tracking.
The below graph shows new oncologic disease cases globally in 2022
Source: Straits Research, Union for International Cancer Control
According to the data mentioned above, breast cancer accounted for the highest number of new cases in 2022, witnessing an 11.60% increase. This rising oncologic disease incidence underscores the urgent need for efficient data management solutions to support healthcare professionals, researchers, and various other sectors in maintaining comprehensive cancer-related records. The growing demand for sophisticated registry software equipped with automation, predictive analytics, and real-time reporting is further driving market expansion.
The adoption of cloud-based cancer registry software is on the rise due to its scalability, cost-effectiveness, and seamless remote accessibility. Cloud-based solutions enable real-time data integration across multiple healthcare centers, enhancing collaboration and efficiency in oncologic disease surveillance. Moreover, they offer automated updates, improved data security, and reduced infrastructure costs compared to traditional on-premise systems.
Thus, the use of cloud-based cancer registry software simplifies oncologic disease registry operations, boosting the cloud-based adoption within the market.
The integration of AI into cancer registry software is significantly improving automation, accuracy, and real-time surveillance. AI-driven models enhance data extraction, minimize manual errors, and facilitate the rapid identification of cancer sites, histology, and biomarkers. This not only increases efficiency but also accelerates the generation of valuable insights for cancer research and policy-making.
As AI-driven solutions continue to advance, their ability to automate complex registry tasks, improve reporting accuracy, and enhance predictive analytics will further propel the adoption of AI-based cancer registry software, fostering market expansion.
The growing global burden of cancer is driving the demand for advanced cancer registry software to improve data-driven decision-making, track patient outcomes, and facilitate research efforts. Efficient data management is essential to monitor cancer trends, evaluate treatment effectiveness, and enhance healthcare planning.
This escalating incidence highlights the urgent need for sophisticated cancer registry software to streamline data collection, enhance cancer surveillance, and support evidence-based treatment strategies, ultimately accelerating market growth.
The demand for high-quality cancer data is increasing as healthcare systems emphasize accurate, timely, and comprehensive information for effective cancer surveillance and treatment planning. Governments, research institutions, and healthcare providers are prioritizing investments in data standardization, automation, and real-time analytics to enhance registry efficiency.
The growing focus on robust cancer data management systems enables better patient tracking, enhances healthcare decision-making, and strengthens public health responses, thereby boosting the market.
Cancer registry software stores vast amounts of highly sensitive patient data, including personal identifiers, diagnostic records, and treatment histories. With the rising number of cyberattacks on healthcare organizations, ensuring data security has become a top priority. Strong encryption protocols, multi-factor authentication, and access control mechanisms are essential to protect this critical information. Compliance with stringent regulations such as HIPAA and GDPR is mandatory, as non-compliance can lead to legal liabilities, financial penalties, and reputational damage. These security concerns may discourage healthcare institutions from adopting or upgrading cancer registry software, ultimately hindering market growth.
Governments globally are increasingly investing in advancing the infrastructure of cancer registries to improve data quality, accuracy, and accessibility. These investments facilitate the uptake of sophisticated software solutions, allowing for effective data management, real-time reporting, and integration with healthcare systems.
Such funding opportunity fuels modernization initiatives, improves data consolidation, and facilitates the development of AI-based insights, boosting market growth opportunities.
| Study Period | 2021-2033 | CAGR | 9.5% |
| Historical Period | 2021-2023 | Forecast Period | 2025-2033 |
| Base Year | 2024 | Base Year Market Size | USD 89.6 million` |
| Forecast Year | 2033 | Forecast Year Market Size | USD 213.8 million |
| Largest Market | North America | Fastest Growing Market | Asia Pacific |
North America dominates the global market, driven by advanced healthcare infrastructure, widespread adoption of digital health solutions, and strong government support for cancer surveillance programs. The U.S. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) and the National Program of Cancer Registries (NPCR) by the Centers for Disease Control and Prevention (CDC) have significantly improved data collection and reporting, with NPCR funding 50 cancer registries. Moreover, rising investments in oncology research, the presence of major market players, and growing awareness about oncologic disease prevention contribute to the region’s market leadership.
Asia-Pacific is expected to witness the fastest CAGR in the global cancer registry software market, fueled by increasing oncologic disease prevalence, healthcare infrastructure investments, and the rising adoption of digital health technologies. Countries like Japan, China, and Australia are heavily investing in cancer surveillance systems to improve early detection and treatment outcomes. For example, China’s National Central Cancer Registry of China (NCCR) plays a crucial role in managing extensive data, supporting research and treatment strategies, and enhancing data accuracy through advanced registry software.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The standalone segment leads the global market due to its customized features and user-friendly interface for efficient cancer data management. This software is designed with advanced data entry, tracking, and reporting tools, making it ideal for specialized oncologic disease registries. For instance, in July 2023, Susan G. Komen launched ShareForCures, a cloud-based breast cancer registry enabling patients to securely share health data for research, addressing data gaps and improving diversity in oncologic disease studies.
On-premises dominates the market, offering greater control over data security, compliance, and customization—crucial for managing sensitive cancer patient records. Hospitals and research institutions prefer on-premises solutions to store data internally, reducing risks from third-party access. Moreover, organizations with robust IT infrastructure favor on-premises deployment for seamless integration with existing systems. This ensures effective data management while maintaining strict regulatory compliance, reinforcing its position as the preferred deployment model in the market.
Commercial leads the global cancer registry software market due to its high-end features, customization options, and comprehensive data management capabilities. These solutions offer seamless integration with healthcare systems, real-time updates, and dedicated customer support, making them the preferred choice for hospitals and research centers. Commercial software providers continuously enhance their platforms with AI-driven analytics and automation tools, further improving efficiency in oncologic disease data tracking, reporting, and patient outcome analysis, driving their dominance in the market.
Governments and third-party organizations lead the market for cancer registry software due to their role in national oncologic disease control programs, regulatory compliance, and significant investments in healthcare infrastructure. For instance, in August 2024, the Surveillance, Epidemiology, and End Results (SEER) Program was highlighted as a key initiative in cancer data collection and analysis. According to the National Cancer Institute (NCI), SEER covers 48% of the U.S. population, serving as an essential tool for researchers, public health officials, and policymakers, driving market growth.
Key players in the cancer registry software market are actively adopting strategic initiatives such as collaborations, product approvals, acquisitions, and new product launches to strengthen their market presence. Companies are focusing on enhancing software capabilities through AI-driven analytics, cloud-based solutions, and interoperability with healthcare systems.
CooperSurgical Inc. is a leading healthcare company specializing in fertility, women’s health, and medical devices. Founded in 1990 and headquartered in Connecticut, U.S., the company offers an extensive portfolio of innovative products and services designed to enhance reproductive health, prenatal care, and surgical solutions.
Recent developments by CooperSurgical Inc.:
As per our analysts, the global cancer registry software market is set for significant growth, fueled by the increasing prevalence of oncologic disease, the growing reliance on real-world data for clinical research, and the expansion of regulatory approvals. Advancements in AI-driven automation and cloud-based solutions are revolutionizing data management, enhancing reporting accuracy, and streamlining registry operations.
Despite these advancements, the market faces challenges, including concerns over data security, interoperability issues across healthcare systems, and the complexities of regulatory compliance. However, governments and healthcare institutions are actively addressing these barriers through stringent data protection laws, standardized reporting frameworks, and increased investments in digital healthcare infrastructure.
Moreover, the expansion of cancer screening programs in high-growth regions like China, Japan, and India is driving demand for robust registry solutions, reinforcing the long-term growth potential of the market.
